# psoriasis - minimax-m3

- Benchmark system: raw
- Repeat: 3
- Task type: DISEASE-STATE
- Tissue / sample source: lesional skin
- Comparison or endpoint: psoriatic lesional skin versus normal control skin
- Answer input cohort: Discovery/Core only
- Selected items: 100
- Input fields: gene name, effect size (log2FC/HR), P value, FDR
- E2seq Agent RAG: disabled
- Conversation memory: disabled
- Thinking mode: disabled
- Held-out validation data in prompt/RAG: no
- Model API: MiniMax / minimax-m3
- Message SHA-256: d1a33d3f606c81814c4fb94a6c63c8f1abebd3bde37d769e82eae4772d8ff873
- Response HTTP status: 200
- Prompt tokens: 4054
- Completion tokens: 11786
- Reasoning tokens: 
- Total tokens: 15840
- API requests reported: 
- Elapsed seconds: 65.579
- Final benchmark system: raw; file rank 2/5; original repeat 3; model vendor: MiniMax

---
<think>The user wants a comprehensive multidimensional interpretation of a transcriptomic dataset comparing psoriatic lesional skin versus normal control skin. Let me carefully analyze the data provided.

The dataset contains gene name, log2FC, P value, and FDR for various genes. Let me first organize the data and identify the most significantly upregulated and downregulated genes.

**Upregulated genes (positive log2FC):**

Top upregulated (by log2FC magnitude):
1. IL36A - log2FC 11.37
2. DEFB4A - log2FC 11.18
3. DEFB4B - log2FC 11.03
4. S100A7A - log2FC 9.83
5. SERPINB4 - log2FC 9.12
6. PI3 - log2FC 9.24
7. S100A7 - log2FC 7.09
8. S100A8 - log2FC 7.73
9. SERPINB3 - log2FC 6.74
10. TCN1 - log2FC 8.04
11. IL36G - log2FC 5.68
12. IL19 - log2FC 7.58
13. IL20 - log2FC 5.67
14. IL26 - log2FC 4.36
15. KRT6A - log2FC 4.30

Key gene families upregulated:
- **IL-36 cytokines**: IL36A, IL36G, IL36RN (note IL36RN is a receptor antagonist, still upregulated)
- **S100 alarmins**: S100A7, S100A7A, S100A8, S100A12
- **Defensins (antimicrobial peptides)**: DEFB4A, DEFB4B, DEFB103A, DEFB103B
- **Serine protease inhibitors**: SERPINB3, SERPINB4, SERPINB11, SERPINB13
- **Small proline-rich proteins (SPRRs)**: SPRR2A, SPRR2B, SPRR2D, SPRR2E, SPRR2F, SPRR2G, SPRR3
- **Late cornified envelope (LCE) proteins**: LCE3A, LCE3D
- **Keratins**: KRT6A (mentioned)
- **Th22/Th17 cytokines**: IL19, IL20, IL26
- **Chemokines**: CXCL13, CXCL8 (CXCL8 not in list but CXCR2 is)
- **Neutrophil-attracting**: CXCR2
- **WNT pathway**: WNT5A
- **Arachidonic acid metabolism**: PLA2G4D, PLA2G4E, AKR1B10, AKR1B15
- **Kynurenine pathway**: KYNU
- **Cell proliferation**: CDK5R1, CCNE1, RRM2, TPBG
- **PD-L1/CD274**: CD274
- **T cell signaling**: PRKCQ (protein kinase C theta - involved in T cell activation)
- **Histamine signaling**: HRH2

**Downregulated genes (negative log2FC):**
1. WAKMAR1 - log2FC -5.63
2. LOC107984452 - log2FC -6.25
3. CYP2W1 - log2FC -4.70
4. BTC (Betacellulin) - log2FC -4.30
5. LOC105371988 - log2FC -4.10
6. LOC107984005 - log2FC -4.27
7. UGT3A2 - log2FC -4.59
8. LINC02660 - log2FC -3.90
9. SAPCD1 - log2FC -2.94
10. SAPCD1-AS1 - log2FC -2.84

The downregulated list is relatively limited in terms of well-characterized protein-coding genes. Most are non-coding RNAs or poorly characterized genes.

Now let me think about the biological programs:

**1. IL-36 / IL-1 family cytokine amplification loop (innate immune activation)**
- IL36A, IL36G, IL36RN (receptor antagonist), IL19, IL20, IL26
- These are key cytokines in psoriasis
- IL-36 cytokines are amplified in psoriatic skin and drive inflammation

**2. Antimicrobial peptide/barrier defense program**
- S100A7, S100A7A, S100A8, S100A12 (alarmins)
- DEFB4A, DEFB4B, DEFB103A, DEFB103B (β-defensins)
- PI3 (elafin)
- SPRR2A-G, SPRR3 (small proline-rich proteins - keratinocyte differentiation)
- LCE3A, LCE3D (late cornified envelope)
- KRT6A (keratin 6, hyperproliferative keratin)
- SERPINB3, B4, B11, B13 (serine protease inhibitors)

**3. Keratinocyte hyperproliferation/differentiation program**
- KRT6A
- SPRR family
- LCE family
- CDK5R1, CCNE1, RRM2 (cell cycle)
- TPBG (trophoblast glycoprotein - Wnt signaling target)

**4. Neutrophil chemotaxis/recruitment**
- CXCR2 (IL-8 receptor)
- CXCL13 (B cell chemokine)
- PLA2G4D, PLA2G4E (arachidonic acid)

**5. Lipid mediator / oxidative stress / aryl hydrocarbon response**
- AKR1B10, AKR1B15 (aldo-keto reductases)
- PLA2G4D, PLA2G4E
- KYNU (kynurenine pathway - tryptophan metabolism)
- CYP2W1 (downregulated - cytochrome P450)

**6. T cell/NK cell signaling**
- IL26 (Th17/Th22 cytokine)
- PRKCQ (T cell signaling)
- CD274 (PD-L1 - immune checkpoint)
- CXCR2

**7. Wnt signaling**
- WNT5A (non-canonical Wnt)
- TPBG

Let me structure my response according to the analysis requirements.

For pathway annotations:
- IL-36 signaling: IL-36 is part of the IL-1 family. IL36A, IL36G signal through IL-36R and MyD88/NF-κB.
- Antimicrobial peptides: GO:0002740 (defense response to bacterium), Reactome "Innate Immune System"
- Keratinization: GO:0031424 (keratinization), Reactome "Keratinization"
- Cell cycle: Hallmark "G2M Checkpoint" - CCNE1, RRM2
- Th17 axis: IL23/IL17/IL22 pathway genes are well-established

Now let me think about the key interactions:

**Key interaction modules:**

1. **IL-36 amplification loop**: IL36A/IL36G → IL36R → MyD88 → NF-κB → more IL36 cytokines, plus cross-talk with IL-17/IL-22 axis. IL36RN is also upregulated but acts as a decoy receptor/antagonist.

2. **Alarmin-IL-17/22 axis**: S100A7/A8/A12, DEFB4 → activate keratinocytes and DCs → amplify Th17 response.

3. **Keratinocyte differentiation barrier module**: SPRRs, LCEs, KRT6A, SERPINBs → cornified envelope formation in hyperplastic psoriatic epidermis.

4. **Neutrophil recruitment axis**: CXCL8 (not in list, but CXCR2 is) → CXCR2 → neutrophil chemotaxis. CXCL13 for B cell recruitment.

5. **Lipid mediator pathway**: PLA2G4D/E → arachidonic acid → inflammatory lipid mediators.

6. **Cell cycle proliferation**: CCNE1, RRM2, CDK5R1.

Let me think about validation priorities:

1. **IL36G/IL36A as therapeutic targets**: Spevigo (spesolimab) and imsidolimab target IL-36R - already clinically validated! This is strong support.

2. **Antimicrobial peptide cluster as biomarkers**: S100A7/A8 and DEFB4 are well-known psoriasis biomarkers.

3. **KYNU/AHR axis**: KYNU generates 3-hydroxyanthranilic acid which is an AHR ligand - links to aryl hydrocarbon receptor signaling and IL-17/22 axis.

4. **Keratinocyte hyperproliferation module**: SPRRs, LCEs, KRT6A - may reflect compensatory vs. pathogenic changes.

5. **PD-L1 (CD274) in psoriatic skin**: Checkpoint molecule upregulation - relevant for understanding immune evasion and chronicity.

Now limitations:
1. **Cell composition effects**: Increased neutrophils, Th17 cells, and altered keratinocyte differentiation could drive many of these gene expression changes.
2. **Tissue heterogeneity**: Bulk RNA-seq doesn't resolve specific cell types.
3. **Treatment effects**: Many psoriasis patients may be on systemic treatments that affect transcription.
4. **Severity and chronicity**: Lesional vs. non-lesional comparisons.
5. **Downregulated genes are sparse and less characterized** - functional interpretation is harder.

Let me also note some less-explored aspects:

- GPR15LG: This is GPR15 ligand, involved in T cell homing to colon but also in skin. GPR15 is involved in T cell trafficking.
- BTC (betacellulin): downregulated - this is an EGFR ligand - interesting given keratinocyte proliferation is increased, suggesting decoupling of EGF-like growth signals.
- CYP2W1 downregulated - reduced xenobiotic metabolism
- ADGRF1 (adhesion G protein-coupled receptor F1) - strongly upregulated, unclear function

Let me also think about the KYNU pathway. KYNU (kynureninase) is in the tryptophan metabolism pathway. IDO1/TDO2 → kynurenine → KYNU → 3-hydroxyanthranilic acid → quinolinic acid. The AHR (aryl hydrocarbon receptor) is activated by tryptophan metabolites and contributes to psoriasis pathogenesis. Also, AHR activation can induce IL-17/22 production and skin inflammation.

The lipid mediator axis: PLA2G4D/PLA2G4E (phospholipases A2 group IVD/E) generate arachidonic acid from phospholipids. AKR1B10/AKR1B15 (aldo-keto reductases) are involved in lipid metabolism and oxidative stress. AKR1B10 is known to be upregulated in psoriasiform dermatitis.

The downregulation of BTC (betacellulin) is interesting - it's an EGFR ligand that promotes keratinocyte differentiation. Its decrease may shift keratinocytes toward hyperproliferation.

The upregulation of PRKCQ (PKC theta) is notable - this is critical for T cell activation and survival. It also has a role in Th17 differentiation.

WNT5A: Non-canonical Wnt ligand, implicated in psoriasis. May drive inflammation through non-canonical Wnt/Ca2+ pathway.

CD274 (PD-L1): Upregulated in psoriatic skin - this is interesting and may represent immune evasion or negative feedback to limit inflammation.

Let me also look at:
- GJB2, GJB6 (connexins 26 and 30) - gap junction proteins involved in keratinocyte differentiation
- SERPINB3, SERPINB4 - serine protease inhibitors that protect against environmental insults
- TCN1 (transcobalamin 1) - B12 binding protein
- KLK13 (kallikrein 13) - protease
- HABP2 (hyaluronan binding protein 2) - coagulation factor
- CYP2W1 - downregulated - reduced xenobiotic metabolism
- ADGRF1 - adhesion GPCR
- LCE3A, LCE3D - late cornified envelope proteins
- KRT6A - keratin 6A - hyperproliferation marker

Now let me put this all together into a coherent response.

Let me structure the response:

1. Overall biological interpretation
2. Core biological programs (max 5)
3. Key genes and interaction modules (max 10)
4. Validation priorities (max 5)
5. Evidence grounding
6. Limitations and alternative explanations

I should also note:
- The dataset shows classic psoriasis signature with extremely high statistical significance (many FDR < 1e-60)
- Most upregulated genes fit established psoriasis biology
- The downregulated genes are more sparse and dominated by non-coding RNAs

Let me draft the response now.

For the core biological programs, I think these 5 are most important:

1. **IL-36/IL-1 family cytokine amplification (innate alarmin-cytokine loop)**
2. **Keratinocyte antimicrobial/barrier defense program** (S100s, defensins, SPRRs, LCEs, KRT6A, SERPINBs)
3. **Hyperproliferative keratinocyte response** (cell cycle + differentiation)
4. **Neutrophil and lymphocyte chemotaxis** (CXCR2, CXCL13, GPR15LG)
5. **Lipid mediator/AHR-tryptophan axis** (PLA2G4s, AKR1Bs, KYNU)

Actually, the keratinocyte hyperproliferation could be merged with the barrier defense since SPRRs, LCEs, KRT6A all relate to epidermal differentiation in psoriatic context. But there are distinct cell cycle genes (CCNE1, RRM2, CDK5R1) so I think it's worth separating.

Let me finalize the response now.

One thing to note: IL36RN is also upregulated, which is interesting because IL-36Ra is a decoy receptor. This is actually a known phenomenon in psoriasis - both the agonist and antagonist are upregulated, but the balance favors agonism. This is an important nuance.

Also, I should mention that IL19, IL20, IL26 are all part of the IL-10/IL-20 family cytokines and are downstream of IL-17A/IL-22. IL-26 in particular has antimicrobial properties.

For the response format, I'll be detailed but avoid redundancy.

Let me also think about evidence grounding:

**Direct evidence from input dataset**: All genes with extremely strong statistics (FDR < 1e-60 for many).

**Pathway/ontology evidence**: GO terms, Reactome pathways.

**Protein interaction evidence**: STRING database interactions, e.g., IL36A/IL36G/IL36R complex; S100A7/S100A8 heterodimer; SERPINB3/B4 co-regulation.

**Disease association evidence**: Many of these genes are in the Open Targets psoriasis database.

**Expression/tissue evidence**: Many are known to be skin/keratinocyte-specific or neutrophil/immune cell-specific.

**Genetic/clinical evidence**: GWAS hits in psoriasis - e.g., TNIP3 has GWAS associations.

**Drug evidence**: Spesolimab/imsidolimab target IL-36R.

OK let me write the response now.

Actually I want to be careful about the very strongly downregulated genes - LOC107984452 has log2FC of -6.25 which is substantial but it's a non-coding locus. WAKMAR1 is a lncRNA - it has been associated with wound healing actually. Let me not overinterpret these.

BTC is the most clearly interpretable downregulated gene - it's a member of the EGF family and a ligand for EGFR and ERBB4. Its downregulation is interesting because psoriasis features epidermal hyperplasia, suggesting that BTC downregulation might be part of a feedback or that the proliferative signal comes from other EGFR ligands (like amphiregulin or HB-EGF) or from other pathways entirely (like KGF/FGF7 from dermal fibroblasts).

CYP2W1 downregulation is interesting - CYP2W1 is a cytochrome P450 enzyme expressed mainly in fetal tissues and adult colon. Its role in psoriasis is unclear.

UGT3A2 is a UDP-glucuronosyltransferase - reduced detoxification capacity?

OK now let me write the final response.

For length, I want to be thorough but not excessive. Let me aim for a comprehensive but focused response.

Let me think about the structure once more:

# Overall biological interpretation
- This is a classic transcriptomic signature of active psoriasis lesional skin
- Dominated by: (1) IL-1 family cytokine amplification (esp IL-36), (2) antimicrobial/alarmin response, (3) altered keratinocyte differentiation with hyperproliferation, (4) neutrophil and lymphocyte recruitment, (5) lipid metabolism/oxidative stress
- Downregulated genes are fewer and dominated by poorly characterized non-coding RNAs and select metabolic genes

# Core biological programs (max 5)

## Program 1: IL-36 family cytokine amplification (innate alarmin axis)
- Direction: Strongly upregulated
- Supporting genes: IL36A (log2FC 11.4), IL36G (5.7), IL36RN (3.0, the receptor antagonist), IL19 (7.6), IL20 (5.7), IL26 (4.4)
- Pathway: Reactome "Interleukin-1 signaling", GO:0032611 (IL-1 beta production)
- Explanation: IL-36A and IL36G are among the most upregulated genes in the dataset. They activate IL-36R → MyD88 → NF-κB/MAPK, driving keratinocyte chemokine production and further IL-36 amplification. IL36RN (IL-36Ra) upregulation is a known feedback. IL19, IL20, IL26 are IL-10 family cytokines induced by IL-17A/IL-22 and reinforce keratinocyte responses.
- Evidence strength: Very high (direct evidence + multiple corroborating genes + therapeutic validation)
- Limitations: Bulk tissue doesn't separate cellular sources; IL36RN induction represents feedback but doesn't negate agonism.

## Program 2: Antimicrobial peptide and alarmin response
- Direction: Strongly upregulated
- Supporting genes: S100A7 (7.1), S100A7A (9.8), S100A8 (7.7), S100A12 (8.3), DEFB4A (11.2), DEFB4B (11.0), DEFB103A (5.8), DEFB103B (5.8), PI3/elafin (9.2), SLC6A14 (4.5)
- Pathway: GO:0042742 (defense response to bacterium), Hallmark "Inflammatory Response"
- Explanation: S100A7/A8/A12 are calcium-binding alarmins released by keratinocytes that activate RAGE/TLR4 and amplify Th17 inflammation. β-defensins and elafin/PI3 are classical antimicrobial peptides whose massive induction (>1000-fold) reflects both barrier breach and direct IL-17/IL-22/IL-36 stimulation. SLC6A14 is an amino acid transporter induced by inflammation.
- Evidence strength: Very high
- Limitations: These markers are not psoriasis-specific (also in atopic dermatitis), so they reflect general barrier inflammation.

## Program 3: Keratinocyte hyperproliferation and altered cornified envelope
- Direction: Strongly upregulated
- Supporting genes: KRT6A (4.3), SPRR2A-G (4.8-7.3), SPRR3 (7.2), LCE3A (8.3), LCE3D (5.3), SERPINB3 (6.7), SERPINB4 (9.1), SERPINB11 (4.5), SERPINB13 (3.1), GJB2 (4.4), GJB6 (3.0), CCNE1 (2.6), RRM2 (2.7), CDK5R1 (2.4)
- Pathway: GO:0031424 (keratinization), Reactome "Keratinization", Hallmark "G2M Checkpoint"
- Explanation: The massive induction of SPRR and LCE genes reflects abnormal terminal differentiation in psoriatic epidermis. KRT6A is a classical hyperproliferation-associated keratin. SERPINBs protect against environmental proteases. GJB2/GJB6 are connexins implicated in psoriatic epidermal communication. Cell cycle genes (CCNE1, RRM2, CDK5R1) support increased keratinocyte proliferation.
- Evidence strength: Very high
- Limitations: Cannot distinguish whether differentiation abnormalities are pathogenic or compensatory.

## Program 4: Immune cell recruitment (neutrophils and lymphocytes)
- Direction: Strongly upregulated
- Supporting genes: CXCR2 (2.7), CXCL13 (5.9), IL26 (4.4), CD274/PD-L1 (3.4), GPR15LG (5.5), PRKCQ (2.9), IL8-inducing genes
- Pathway: GO:0030593 (neutrophil chemotaxis), Reactome "Chemokine signaling"
- Explanation: CXCR2 is the neutrophil receptor for CXCL1/2/5/8 and its upregulation on keratinocytes/skin-resident cells enhances neutrophil recruitment - explaining Munro microabscess formation. CXCL13 recruits B cells/CXCR5+ T follicular helper cells. PRKCQ is essential for T cell activation and Th17 differentiation. CD274/PD-L1 may reflect immune exhaustion or feedback. GPR15LG is a chemokine for GPR15+ T cells that home to skin.
- Evidence strength: High
- Limitations: Bulk expression cannot determine which cell types express these genes.

## Program 5: Lipid mediator and aryl hydrocarbon receptor metabolism
- Direction: Mixed (PLA2G4D/E and AKR1B10/15 upregulated; CYP2W1 downregulated)
- Supporting genes: PLA2G4D (4.6), PLA2G4E (2.5), AKR1B10 (6.3), AKR1B15 (5.2), KYNU (4.4)
- Pathway: KEGG "Arachidonic acid metabolism", Reactome "Synthesis of leukotrienes and lipoxins"
- Explanation: PLA2G4D/E generate arachidonic acid substrate for eicosanoid production. AKR1B10 is an aldose reductase known to be induced by IL-17/IL-22 and NRF2 activation in keratinocytes. KYNU is a tryptophan-metabolizing enzyme in the kynurenine pathway whose products activate the aryl hydrocarbon receptor (AHR), a known amplifier of IL-17/IL-22 responses.
- Evidence strength: Moderate (multiple genes but biological connection less canonical)
- Limitations: Bulk expression doesn't localize these to specific cell types; AHR signaling is bidirectional in psoriasis.

OK these are the 5 programs. Let me also briefly mention the downregulated signals.

Downregulated genes: WAKMAR1 (lncRNA), BTC (betacellulin), CYP2W1, UGT3A2, SAPCD1 - mostly uncharacterized or metabolic. The downregulation of BTC is notable as an EGFR ligand whose loss may indicate a shift away from normal differentiation signaling.

# Key genes and interaction modules (max 10)

1. IL36A/IL36G/IL36R axis - direct protein interaction (IL36A and IL36G bind IL36R); IL36A is the most upregulated gene with log2FC 11.4.

2. S100A8/S100A7 heterodimer and their receptor RAGE - protein-protein interaction; alarmins.

3. DEFB4A/B cluster - co-located in 8p23.1; co-regulated by IL-17/IL-22/IL-36; direct genomic duplication.

4. SPRR2 family - co-expression; shared regulatory program (likely AP-1 driven).

5. SERPINB3/B4 cluster at 18q21 - co-regulated by IL-17/IL-22; functional interaction as protease inhibitors.

6. KYNU-AHR axis - pathway co-membership (tryptophan metabolism → AHR activation).

7. PLA2G4D/AKR1B10 lipid mediator module - co-expression in lipid metabolism pathway.

8. CXCL13-CXCR5 (not in list) B cell axis - pathway co-membership.

9. IL19/IL20/IL26-IL20R axis - receptor-mediated; downstream of IL-17A.

10. CCNE1/RRM2 cell cycle module - co-expression; proliferation.

# Validation priorities (max 5)

1. **IL-36 axis as therapeutic target** (Established evidence / Therapeutic target): Already validated clinically (spesolimab, imsidolimab). Confirm whether response/non-response correlates with baseline IL36G expression.

2. **KYNU-AHR axis as mechanistic driver** (Supported hypothesis / Mechanistic): KYNU upregulation may indicate AHR activation. Test whether pharmacological AHR inhibition reduces IL-17/IL-22-driven inflammation.

3. **SPRR/LCE/SERPINB module as biomarker of disease activity** (Supported hypothesis / Biomarker): These proteins are easily measurable in serum or tape-strip skin. Test whether they correlate with PASI scores.

4. **PLA2G4D as therapeutic target** (Exploratory hypothesis / Therapeutic target): Emerging target in psoriasis and atopic dermatitis. Test whether PLA2G4D inhibition reduces eicosanoid production in psoriatic skin.

5. **Cellular source deconvolution** (Confounding or composition check / Methodological): Use single-cell RNA-seq or spatial transcriptomics to determine which upregulated genes are from keratinocytes vs. infiltrating immune cells vs. endothelium.

# Evidence grounding

I will provide this throughout the response.

# Limitations

1. Bulk tissue RNA-seq - cannot resolve cell type contributions. Major genes may be dominated by infiltrating neutrophils (CXCR2, IL36A, DEFB4A, PI3 are all neutrophil-affiliated).

2. Tissue composition bias - lesional skin has more immune infiltrate than normal skin, which could drive many apparent changes.

3. Lack of clinical metadata (treatment, severity, duration, age, sex).

4. Sparse downregulated gene list limits insights into pathways that are LOST.

5. The very high effect sizes (log2FC 11+) likely reflect contributions from cell types largely absent in normal skin (e.g., neutrophils and infiltrating immune cells).

OK let me write the full response now in a clear, well-organized format.

I want to make sure I cite genes with their actual log2FC values and statistical significance to ground the analysis in the data.

Let me finalize the structure:

## 1. Overall Biological Interpretation

Brief overview (1-2 paragraphs).

## 2. Core Biological Programs (5)

Each with:
- Program name
- Direction
- Major supporting genes (with statistics)
- Pathway
- Explanation
- Evidence strength and limitations

## 3. Key Genes and Interaction Modules (10)

Each with:
- Direction
- Role
- Interaction type

## 4. Validation Priorities (5)

Each with classification, why prioritized, evidence, conclusion type.

## 5. Evidence Grounding

Brief synthesis.

## 6. Limitations and Alternative Explanations (5)

Let me write this out now.</think>

# Multidimensional Interpretation: Psoriatic Lesional Skin vs. Normal Control Skin

## 1. Overall Biological Interpretation

The transcriptomic signature reported here is a canonical and statistically overwhelming psoriatic lesional-skin program, with the most extreme effect sizes in the entire differential expression set exceeding log₂FC = 11 (IL36A, DEFB4A/B) and FDRs routinely below 1 × 10⁻⁶⁰. Functionally, the signature is dominated by:

- **A coordinated innate cytokine alarm loop** centered on IL-36 family agonizts (IL36A/G), with co-amplified IL-19/IL-20/IL-26 and the antagonist IL36RN;
- **A massive keratinocyte antimicrobial/barrier-defense response** featuring S100 alarmins (S100A7/A7A/A8/A12), β-defensins (DEFB4A/B, DEFB103A/B), elafin (PI3), and the SPRR/LCE/SERPINB cornified-envelope module;
- **Hyperproliferative epidermal remodeling** with cell-cycle activation (CCNE1, RRM2) and altered keratinocyte differentiation (KRT6A, GJB2/GJB6);
- **Immune-cell recruitment cues** (CXCR2, CXCL13, GPR15LG, PRKCQ, CD274);
- **A metabolic/lipid-mediator axis** (PLA2G4D/E, AKR1B10/15, KYNU) connected to the aryl-hydrocarbon receptor (AHR) pathway.

The downregulated arm is comparatively sparse and dominated by uncharacterized or weakly annotated loci (LOC107984452, WAKMAR1, SAPCD1/SAPCD1-AS1) plus a few interpretable metabolic loci (BTC, CYP2W1, UGT3A2). This asymmetry — broad, very strong induction of immunobarrier genes versus a thin, lower-information repressed set — is itself diagnostically informative and consistent with the lesional psoriatic state being driven more by *addition* of effector programs than by *loss* of homeostatic ones.

---

## 2. Core Biological Programs

### Program 1 — IL-36 / IL-1-family cytokine amplification loop (innate alarmin axis)

- **Direction:** Strongly upregulated in lesional skin.
- **Major supporting genes (current dataset):**
  - IL36A (log₂FC = +11.37, FDR ≈ 1.7 × 10⁻⁹⁸) — among the top effect sizes in the entire table.
  - IL36G (log₂FC = +5.68, FDR ≈ 1.4 × 10⁻⁹⁰).
  - IL36RN (log₂FC = +3.00, FDR ≈ 3.9 × 10⁻⁶²) — the natural antagonist.
  - IL19 (+7.58), IL20 (+5.67), IL26 (+4.36) — downstream IL-10/IL-20-family effectors of IL-17/IL-22.
- **Most appropriate pathway:** Reactome *“Interleukin-1 family signaling”*; GO:0032611 *“interleukin-1 production”*; overlapping with Hallmark *“Inflammatory Response.”*
- **Why these genes indicate this program:** IL36A/G are direct IL-1-family cytokines that signal through IL-36R → MyD88 → NF-κB/MAPK and are themselves NF-κB targets, generating a self-amplifying keratinocyte–dendritic cell loop. The concomitant induction of IL36RN is a known autoregulatory feedback that is overwhelmed by agonist induction. The parallel upregulation of IL19/IL20/IL26 places this axis in the broader IL-17/IL-22 → keratinocyte cytokine cascade.
- **Evidence strength and limitations:** The dataset provides very strong direct evidence for IL-36 family induction; clinical therapeutic validation exists (anti–IL-36R antibodies — see Program 1 in §4). A limitation is that IL36A/G are also abundantly expressed by neutrophils infiltrating lesional skin, so a meaningful fraction of the signal may be composition-driven rather than keratinocyte-intrinsic.

### Program 2 — Antimicrobial peptide and alarmin barrier response

- **Direction:** Strongly upregulated in lesional skin.
- **Major supporting genes (current dataset):**
  - β-defensins: DEFB4A (+11.18), DEFB4B (+11.03), DEFB103A (+5.76), DEFB103B (+5.75).
  - S100 alarmins: S100A7A (+9.83), S100A12 (+8.33), S100A8 (+7.73), S100A7 (+7.09).
  - Elafin: PI3 (+9.24).
  - Other: TCN1 (+8.04), SLC6A14 (+4.47), HRH2 (+3.27), TRIM10 (+4.04), PRSS27 (+4.24), KLK13 (+4.05).
- **Most appropriate pathway:** GO:0042742 *“defense response to bacterium”*; Reactome *“Innate Immune System”*; Hallmark *“Inflammatory Response.”*
- **Why these genes indicate this program:** This cluster is the textbook IL-17/IL-22/IL-36 transcriptional output of keratinocytes and infiltrating neutrophils. The S100 family members form heterodimers (e.g., S100A8/A9) that signal through TLR4/RAGE; defensins and PI3 are antimicrobial peptides also implicated in keratinocyte chemokine/IL-36 amplification. SLC6A14 (an amino-acid transporter induced by inflammatory cytokines) supports the metabolic demands of proliferating keratinocytes and infiltrating leukocytes.
- **Evidence strength and limitations:** Direct dataset evidence is exceptionally strong (the largest effect sizes in the table). The pattern is, however, not psoriasis-specific — it is shared with atopic dermatitis and other Th2/Th17-driven skin inflammation. A second limitation is that DEFB4A and PI3 are strongly expressed by neutrophils; their extreme log₂FC likely reflects both keratinocyte induction and neutrophil infiltration.

### Program 3 — Altered epidermal cornified envelope and keratinocyte hyperproliferation

- **Direction:** Strongly upregulated (cell-cycle and structural envelope genes).
- **Major supporting genes (current dataset):**
  - SPRR2 family: SPRR2A (+7.31), SPRR2F (+7.22), SPRR2G (+4.75), SPRR2D (+5.92), SPRR2B (+6.38), SPRR2E (+3.99), SPRR3 (+7.18).
  - LCE3A (+8.30), LCE3D (+5.31).
  - SERPINB4 (+9.12), SERPINB3 (+6.74), SERPINB11 (+4.47), SERPINB13 (+3.09).
  - KRT6A (+4.30); GJB2 (+4.42), GJB6 (+3.02).
  - Cell-cycle: CCNE1 (+2.56), RRM2 (+2.72), CDK5R1 (+2.35), TPBG (+1.86).
- **Most appropriate pathway:** GO:0031424 *“keratinization”*; Reactome *“Keratinization”* / *“Formation of the cornified envelope”*; Hallmark *“G2M Checkpoint”* (CCNE1, RRM2).
- **Why these genes indicate this program:** SPRR2 and LCE3 family proteins are structural components of the cornified envelope whose massive induction reflects the abnormal, accelerated terminal differentiation program of psoriatic epidermis. SERPINB3/B4 (the *SCCA1/2* proteins) are squamous-cell serpins that protect against exogenous and endogenous proteases and are well-established IL-17/IL-22 transcriptional targets. KRT6A is a canonical wound-healing/hyperproliferation keratin. Concurrently, induction of CCNE1, RRM2, and CDK5R1 indicates that proliferative machinery is engaged in basal/suprabasal keratinocytes, while TPBG is a known Wnt target with relevance to epidermal remodeling.
- **Evidence strength and limitations:** Direct evidence is very strong. Limitations: it is difficult to disentangle whether the abnormal differentiation program is *pathogenic* (driving disease) versus *compensatory* (responding to barrier breach), and bulk tissue obscures whether a given gene originates from the basal, spinous, or granular compartment.

### Program 4 — Immune-cell chemotaxis and adaptive-immune effector signaling

- **Direction:** Strongly upregulated.
- **Major supporting genes (current dataset):**
  - CXCR2 (+2.70) — neutrophil chemokine receptor.
  - CXCL13 (+5.89) — B-cell / T-follicular-helper chemokine.
  - GPR15LG (+5.52) — ligand for the GPR15 skin-homing receptor.
  - PRKCQ (+2.88) — PKC-θ, essential for T-cell receptor signaling and Th17 differentiation.
  - CD274 (+3.44) — PD-L1.
  - IL26 (+4.36) — Th17/Th22 cytotoxic cytokine with antimicrobial activity.
  - WNT5A (+2.53) — non-canonical Wnt ligand implicated in inflammatory crosstalk.
- **Most appropriate pathway:** GO:0030593 *“neutrophil chemotaxis”*; GO:0006955 *“immune response”*; Reactome *“Chemokine signaling”*.
- **Why these genes indicate this program:** CXCR2 upregulation on keratinocytes/resident cells amplifies neutrophil recruitment via CXCL1/2/5/8, explaining Munro’s microabscesses. CXCL13 is a hallmark of lymphoid-cluster formation. PRKCQ is a T-cell-intrinsic signaling kinase whose induction in lesional skin reflects T-cell infiltration and activation. CD274 (PD-L1) upregulation is consistent with chronic antigen-driven negative feedback on T cells and may contribute to local immune “exhaustion” within plaques.
- **Evidence strength and limitations:** Direct dataset evidence is strong. A key limitation is that bulk RNA cannot distinguish whether each transcript comes from infiltrating lymphocytes (PRKCQ, IL26) versus resident keratinocytes (CXCR2, WNT5A); single-cell or spatial validation would clarify cellular origin.

### Program 5 — Lipid-mediator, oxidative-stress, and tryptophan/AHR metabolism

- **Direction:** Mixed; predominantly upregulated, with selective metabolic repression.
- **Major supporting genes (current dataset):**
  - PLA2G4D (+4.61), PLA2G4E (+2.47) — cytosolic phospholipases A₂ that liberate arachidonic acid.
  - AKR1B10 (+6.27), AKR1B15 (+5.23) — aldo-keto reductases linked to oxidative/lipid stress and IL-17/IL-22 induction.
  - KYNU (+4.42) — kynureninase in the tryptophan → kynurenine → AHR-ligand pathway.
  - HEPHL1 (+6.33) — a metallo-oxidase; ARSF (+3.65); GDA (+5.90).
  - *Downregulated:* CYP2W1 (−4.70), UGT3A2 (−4.59) — xenobiotic-metabolizing enzymes.
- **Most appropriate pathway:** KEGG *“Arachidonic acid metabolism”* / *“Tryptophan metabolism”*; Reactome *“Synthesis of leukotrienes and lipoxins”*; GO:0006690 *“icosanoid metabolic process.”*
- **Why these genes indicate this program:** PLA2G4D/E generate the substrate pool for cyclooxygenase/lipoxygenase pathways producing prostaglandins and leukotrienes in psoriatic skin. AKR1B10 is a known NRF2- and IL-17/IL-22-inducible keratinocyte gene linked to oxidative stress and lipid aldehyde detoxification. KYNU completes tryptophan catabolism to 3-hydroxyanthranilate and quinolinate, which are endogenous AHR ligands; AHR activation is a recognized amplifier of IL-17/IL-22 signaling. The simultaneous *reduction* in CYP2W1 and UGT3A2 suggests a loss of xenobiotic/drug-metabolizing capacity in lesional keratinocytes.
- **Evidence strength and limitations:** Direct evidence is good across multiple genes, but the *program* (linking lipid mediators to AHR activation) is inferred from pathway co-membership rather than demonstrated in this dataset. The downregulated xenobiotic-metabolism signal is intriguing but small in gene number and needs external replication.

---

## 3. Key Genes and Interaction Modules

The following ten entities capture the most informative signals, integrating magnitude, statistical confidence, and network position.

1. **IL36A / IL36G / IL36RN — agonist–antagonist feedback module**
 - Statistical direction: IL36A +11.37 / IL36G +5.68 / IL36RN +3.00.
 - Role: Anchors Program 1; IL36A/G signal through IL-36R (direct receptor–ligand interaction), while IL36RN acts as a decoy receptor.
 - Interaction type: Direct receptor–ligand binding; NF-κB-driven transcriptional co-regulation (co-expression, regulatory).

2. **S100A7 / S100A7A / S100A8 / S100A12 — alarmin network**
 - Statistical direction: All strongly upregulated (+7.1 to +9.8).
 - Role: Anchors Program 2; calcium-binding alarmins that engage RAGE/TLR4 and amplify keratinocyte chemokine/IL-36 production.
 - Interaction type: Direct protein heterodimerization (e.g., S100A8/A9-like), receptor binding, and transcriptional co-regulation (co-expression).

3. **DEFB4A / DEFB4B — co-amplified defensin module**
 - Statistical direction: +11.18 / +11.03 (largest log₂FC in the table).
 - Role: Antimicrobial peptide effectors in Program 2; both are direct IL-17A/IL-22/IL-36 transcriptional targets.
 - Interaction type: Genomic tandem duplication / co-regulation; they should be regarded as a single co-regulated locus, not as independent biomarkers.

4. **SPRR2A/B/D/E/F/G + SPRR3 + LCE3A/LCE3D — cornified-envelope module**
 - Statistical direction: +3.99 to +8.30.
 - Role: Anchors Program 3; reflects abnormal keratinocyte terminal differentiation in psoriatic plaques.
 - Interaction type: Co-expression within the same epidermal differentiation cluster; pathway co-membership in keratinization.

5. **SERPINB3 / SERPINB4 — squamous serpin module**
 - Statistical direction: +6.74 / +9.12.
 - Role: Anchors Program 3; serine protease inhibitors induced by IL-17/IL-22 that dampen desquamation-related protease activity.
 - Interaction type: Co-regulated tandem gene pair; co-expression and pathway co-membership (they form heterodimers, but heterodimerization in this dataset is inferred from prior literature, not direct evidence here).

6. **CCNE1 / RRM2 / CDK5R1 — proliferation module**
 - Statistical direction: +2.35 to +2.72.
 - Role: Anchors the proliferative arm of Program 3.
 - Interaction type: Functional pathway co-membership (G1/S and DNA-replication machinery); not direct physical interaction.

7. **KYNU–AHR axis (putative)**
 - Statistical direction: KYNU +4.42.
 - Role: Bridges Programs 1 and 5; tryptophan catabolism generates endogenous AHR ligands, which amplify IL-17/IL-22 transcription.
 - Interaction type: Pathway co-membership (tryptophan metabolism → AHR); no direct physical interaction implied.

8. **PLA2G4D / PLA2G4E / AKR1B10 / AKR1B15 — lipid/oxidative-stress module**
 - Statistical direction: PLA2G4D +4.61, PLA2G4E +2.47, AKR1B10 +6.27, AKR1B15 +5.23.
 - Role: Anchors Program 5; substrate provision for eicosanoids plus reductive detoxification of lipid aldehydes.
 - Interaction type: Pathway co-membership (arachidonic acid cascade); co-expression.

9. **CXCR2 + CXCL13 — chemokine-recruitment module**
 - Statistical direction: CXCR2 +2.70, CXCL13 +5.89.
 - Role: Anchors Program 4; neutrophil chemotaxis (CXCR2) and B-cell / Tfh recruitment (CXCL13–CXCR5 axis).
 - Interaction type: Receptor–ligand interaction (CXCR2 with CXCL1/2/5/8; CXCL13 with CXCR5 — the latter not in the table, so the CXCL13 side is inferred).

10. **PRKCQ + CD274 — T-cell signaling / immune-checkpoint module**
 - Statistical direction: PRKCQ +2.88, CD274 +3.44.
 - Role: Adaptive-immune effector and feedback brake; their joint induction suggests active T-cell infiltration with concurrent negative feedback.
 - Interaction type: Functional/co-expression module; no direct physical interaction.

*Two notable downregulated loci are also flagged for context rather than inclusion in the core module list:* **BTC (−4.30)**, an EGFR-family ligand whose loss may indicate decoupling of normal EGF-driven differentiation; and **WAKMAR1 (−5.63)**, a wound-healing-associated lncRNA whose loss has been described in chronic inflammation but whose function remains poorly characterized.

---

## 4. Validation Priorities

### Priority 1 — IL-36 axis as therapeutic target
- **Classification:** Therapeutic target.
- **Why prioritized:** IL36A is the most upregulated gene in the dataset (log₂FC = +11.37) and IL36G is also among the strongest signals. The pathway is supported by multiple, mutually reinforcing IL-1-family genes.
- **Dataset evidence:** Direct, very high effect sizes and FDRs.
- **External evidence:** *Established evidence* — anti–IL-36R monoclonal antibodies (spesolimab, imsidolimab) have demonstrated clinical efficacy in generalized pustular psoriasis; the dataset is therefore congruent with, and partly explains, that clinical result.
- **Next step:** Test whether baseline lesional IL36A/G mRNA or protein levels predict response to anti–IL-36R therapy in plaque psoriasis.
- **Status:** Established evidence for IL-36R as a target in pustular psoriasis; *supported hypothesis* in plaque psoriasis.

### Priority 2 — KYNU–AHR axis as a mechanistic amplifier
- **Classification:** Mechanistic hypothesis.
- **Why prioritized:** KYNU links tryptophan catabolism (an emerging psoriasis pathway) to AHR, which transcriptionally cooperates with the IL-17/IL-22 axis. The dataset shows clear KYNU induction (+4.42), but no direct AHR read-out is included.
- **Dataset evidence:** Direct KYNU induction; supporting pathway context from Reactome *“Tryptophan catabolism.”*
- **External evidence:** *Supported hypothesis* — AHR activation by tryptophan metabolites is documented in cutaneous inflammation; pharmacological AHR modulation has been tested with coal tar and tapinarof.
- **Next step:** Quantify AHR transcriptional targets (e.g., CYP1A1, AHRR) and kynurenine-pathway intermediates in lesional vs. non-lesional skin, and test whether AHR antagonism reduces IL-17/IL-22-driven keratinocyte responses.
- **Status:** Supported hypothesis.

### Priority 3 — SPRR2/LCE/SERPINB cornified-envelope module as a serum/tape-strip biomarker of disease activity
- **Classification:** Biomarker.
- **Why prioritized:** These are robustly induced (+4 to +9 log₂FC), secreted/measurable in skin and body fluids, and not directly targeted by current biologics (so their signal will not be pharmacologically silenced). They could provide orthogonal read-outs to PASI.
- **Dataset evidence:** Multiple strongly upregulated genes; co-regulated module.
- **External evidence:** *Supported hypothesis* — SERPINB3/B4 and S100A7/A8 are already described as elevated in psoriatic serum and tape-strip samples.
- **Next step:** Measure SERPINB3/B4 and SPRR2 proteins by ELISA in serum or by LC-MS in tape-stripped stratum corneum, and correlate with PASI and histological acanthosis.
- **Status:** Supported hypothesis.

### Priority 4 — PLA2G4D as a tractable inflammatory-lipid target
- **Classification:** Therapeutic target.
- **Why prioritized:** PLA2G4D (+4.61) is a cytosolic phospholipase with relatively restricted expression and emerging pharmacology. Its induction implies substrate supply for downstream eicosanoid production, which is a non-redundant axis relative to IL-17/IL-22/IL-36 blockade.
- **Dataset evidence:** Strong, specific induction.
- **External evidence:** *Exploratory hypothesis* — PLA2G4D inhibitors are under preclinical investigation for skin inflammation; clinical efficacy in psoriasis is not yet established.
- **Next step:** Stratify lesional skin by IL-17/IL-22-inhibitor responder status and assess whether PLA2G4D expression correlates with residual disease activity or with eicosanoid levels.
- **Status:** Exploratory hypothesis. *The mere existence of a chemical tool compound should not be interpreted as clinical therapeutic validation.*

### Priority 5 — Cellular-source deconvolution and composition-aware re-analysis
- **Classification:** Confounding or composition check.
- **Why prioritized:** Many of the strongest signals (IL36A, DEFB4A/B, PI3, CXCR2, S100A8/A12, IL26) are produced by neutrophils and infiltrating lymphocytes rather than keratinocytes. A substantial fraction of the apparent “keratinocyte” signal could therefore be an immune-infiltration artifact.
- **Dataset evidence:** The list contains well-known neutrophil and T-cell markers, but the bulk design cannot assign cellular origin.
- **External evidence:** Single-cell RNA-seq studies in psoriasis have already mapped many of these transcripts to neutrophils and T cells.
- **Next step:** Re-analyse the differential expression after deconvolution of bulk RNA-seq using published psoriasis scRNA-seq references, or perform paired spatial transcriptomics.
- **Status:** Methodological priority; not a biological finding per se, but essential for proper interpretation of the other four priorities.

---

## 5. Evidence Grounding

For each major conclusion I have relied on the following evidence categories, with their independence assessed:

- **Direct dataset evidence:** All gene-level statistics (log₂FC, P, FDR) originate from the input table. This is the only source for effect direction and magnitude.
- **Pathway/ontology evidence (GO, Reactome, KEGG, Hallmark):** Used for program-level interpretation. These are derived from curated prior literature and are not independent of the disease-association evidence below; they share underlying sources (e.g., Reactome *“Keratinization”* and GO *“keratinization”* derive from overlapping experimental literature).
- **Disease-association evidence:** Long-standing descriptions of IL36A/G, S100A7/A8, DEFB4A, KRT6A, and SERPINB3/B4 as psoriasis biomarkers provide *corroborating but not independent* support — many of these associations were established using earlier psoriatic transcriptomes that overlap in conceptual content with the current dataset.
- **Drug/therapeutic evidence:** Anti–IL-36R antibodies and IL-17/IL-22 inhibitors provide *independent* pharmacological validation of Programs 1 and 4, respectively. Their existence does not by itself validate other upregulated genes as therapeutic targets.
- **Expression/tissue-specific evidence:** Tissue-restricted expression of SPRR/LCE/SERPINB genes in stratified squamous epithelia, and of DEFB4A in neutrophils/keratinocytes, supports Programs 2 and 3 but is again non-independent of the ontology evidence above.
- **Protein-interaction / regulatory evidence:** Direct physical interaction evidence (heterodimerization, receptor–ligand binding) is drawn from external sources and is independent of the input differential expression statistics.
- **Genetic/clinical evidence:** TNIP3 (GWAS hit in psoriasis) is present in the table (+7.28), supporting an inflammatory/NF-κB regulatory program; this is an *independent* line of evidence for at least one of the five programs.

**No conflicting evidence** was identified between the input dataset and established psoriasis biology. The single area of potential tension is the *interpretation* of downregulated genes: the dataset shows modest downregulation of metabolic loci (CYP2W1, UGT3A2, BTC) without sufficient supporting genes to construct a confident “loss-of-function” program; this is *insufficient evidence* for a coordinated repressed pathway.

---

## 6. Limitations and Alternative Explanations

1. **Tissue-composition confounding (most significant concern).** Lesional psoriatic skin contains dense neutrophilic, lymphocytic, and dendritic-cell infiltrates that are sparse in normal skin. Genes such as IL36A, DEFB4A/B, PI3, S100A8/A12, IL26, CXCR2, and PRKCQ are known to be highly expressed by these infiltrating cells. A meaningful portion of the observed differential expression may therefore reflect changes in *cellular composition* rather than in *transcriptional state of resident cells*. This can be distinguished by single-cell RNA-seq or spatial transcriptomics, or by computational deconvolution of the bulk data.

2. **Unknown clinical metadata.** The analysis does not specify treatment status, disease duration, body-site of biopsy, PASI score, age, or sex. Treatment with topical steroids, vitamin-D analogues, or prior systemic biologics substantially attenuates IL-17/IL-22/IL-36 and antimicrobial-peptide signatures and would confound interpretation. Ideally, an analysis stratified by treatment-naïve status would be performed.

3. **Sparser and less informative downregulated arm.** Only ~10 of the most significant genes are downregulated, and several are uncharacterized lincRNAs (WAKMAR1, LOC107984452) or antisense transcripts (SAPCD1-AS1). This limits the ability to derive repressed-pathway hypotheses and biases interpretation toward *addition* of effector programs.

4. **Bulk resolution limits mechanistic inference.** Statements about “keratinocyte” versus “immune-cell” gene programs cannot be made directly from these data; the assignment is inferred from external sources and is therefore not independent. In particular, co-expression of SPRR2/SERPINB/KRT6A genes with IL36A and DEFB4A in the same bulk sample does not mean these transcripts arise from the same cells.

5. **Possible cohort/platform/batch effects.** The very large effect sizes (log₂FC > 9) and uniformly extreme FDRs are consistent with strong biology, but could also be amplified by platform-specific capture biases (e.g., over-representation of antimicrobial-peptide transcripts by poly-A selection vs. ribodepletion; lncRNA under-representation by poly-A selection). This is *plausible but unverified* without access to the protocol; independent replication on an orthogonal platform would strengthen confidence.

A practical mitigation for items (1)–(3) would be a re-analysis restricted to treatment-naïve samples with paired non-lesional controls, accompanied by cell-type deconvolution. Until then, the conclusions above should be treated as **well-supported hypotheses for Programs 1–4 and a more exploratory characterization for Program 5**, with the strong caveat that a substantial fraction of the signal amplitude in Programs 1–2 is plausibly composition-driven.
